| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
VEGFR1 (IC50 = 2 nM); VEGFR2 (IC50 = 50 nM); PDGFRβ (IC50 = 4 nM); KIT (IC50 = 15 nM)
SU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), KIT, and fms-like tyrosine kinase 3 (FLT-3). It shows IC50s of 50 nM for VEGFR2, 2 nM for VEGFR1, 4 nM for PDGFRβ, and 15 nM for KIT. By inhibiting these receptors, SU14813 blocks angiogenesis and tumor cell proliferation. It is a next-generation TKI developed following sunitinib, designed to exhibit optimized PK and tolerability profiles. |
|---|---|
| ln Vitro |
SU14813 suppresses the growth, migration, and survival of endothelial cells and/or tumor cells that express these targets both in ligand-dependent and ligand-independent ways. When it comes to transfected NIH 3T3 cells, FLT3-internal tandem duplication (FLT3-ITD; MV4;11 cells), KIT (Mo7e cells), PDGFR-β (transfected NIH 3T3 cells), and FMS/CSF1R (transfected NIH 3T3 cells), SU14813 inhibits their cellular ligand-dependent phosphorylation. In pig aorta endothelial cells overexpressing VEGFR-2, PDGFR-β, and KIT phosphorylation, SU14813 inhibits these processes with cellular IC50 values of 5.2, 9.9, and 11.2 nM, respectively. U-118MG's growth is inhibited by SU14813, with an IC50 of 50–100 nM[1].
In vitro, SU14813 demonstrates broad and potent antitumor activity equivalent to that of sunitinib. It inhibits VEGFR2 with an IC50 of 50 nM, VEGFR1 with 2 nM, PDGFRβ with 4 nM, and KIT with 15 nM. Its in vitro activity is characterized by potent inhibition of multiple receptor tyrosine kinases involved in angiogenesis and tumor growth. SU14813 is used as a research tool to study multi-targeted kinase inhibition. |
| ln Vivo |
SU14813 exhibits dose- and time-dependent inhibition of VEGFR-2, PDGFR-β, and FLT3 phosphorylation in xenograft tumors. An estimated 100–200 ng/mL of plasma is needed for in vivo target inhibition. When SU14813 is used as a monotherapy, it shows extensive and strong antitumor activity that causes growth arrest, regression, or a significant reduction in the growth of different established xenografts made from tumor cell lines in rats or humans. When treatment is combined with docetaxel, compared to when either drug is administered alone, both the inhibition of primary tumor growth and the survival of the tumor-bearing mice are significantly increased[1].
In vivo, SU14813 reduces tumor growth in human acute myeloid leukemia, renal, and colon cancer, as well as rat glioma, mouse xenograft models when used at doses ranging from 10 to 80 mg/kg twice per day. It demonstrates broad and potent antitumor activity equivalent to that of sunitinib, which resulted in tumor regression, growth arrest, growth delay, and prolonged survival in established xenograft cancer models in mice. Its in vivo efficacy is attributed to its multi-targeted kinase inhibition. |
| Enzyme Assay |
In vitro enzyme assays for SU14813 typically involve measuring the inhibition of various receptor tyrosine kinases, including VEGFR1, VEGFR2, PDGFRβ, and KIT. The compound shows IC50s of 2 nM for VEGFR1, 50 nM for VEGFR2, 4 nM for PDGFRβ, and 15 nM for KIT. These assays confirm the compound's mechanism of action as a multi-targeted TKI.
|
| Cell Assay |
The impact of SU14813 on the survival of endothelial cells is assessed. Human umbilical vein endothelial cells in passages 4 through 5 are cultured to subconfluency in EGM2 medium with 10% FBS, endothelial cell growth supplement, and 10 μg/mL sodium heparin. Ten thousand cells per well of F12K medium containing 10% FBS are seeded in 96-well plates. After starving the cells in F12K+1% FBS for eighteen hours the following day, SU14813 is added to the cells at different concentrations. After forty-five minutes, the assay is reconstituted with 20 ng/mL of growth factor (VEGF or basic fibroblast growth factor, bFGF). The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay is used to calculate cell counts three days later[1].
In vitro cellular assays for SU14813 typically involve treating cancer cell lines with the compound and measuring cell proliferation, apoptosis, or signaling pathway modulation. The compound inhibits multiple receptor tyrosine kinases, leading to the modulation of downstream signaling pathways. These cell-based studies demonstrate the compound's broad-spectrum inhibitory activity. |
| Animal Protocol |
Mouse: In a murine LLC model resistant to docetaxel, SU14813's effectiveness and synergism with the microtubule inhibitor docetaxel are assessed. On day five following tumor implantation, SU14813 is given p.o. twice daily (BID) at doses of 10, 40, 80, or 120 mg/kg. Commencing on day 5 following tumor implantation, docetaxel 40 mg/kg (the maximum tolerated dose in mice) is injected intravenously three times a week[1].
In vivo animal models for SU14813 include xenograft tumor models of human acute myeloid leukemia, renal, and colon cancer, as well as rat glioma models. The compound is administered orally at doses ranging from 10 to 80 mg/kg twice per day. SU14813 reduces tumor growth in these models. These studies provide evidence for the compound's in vivo antitumor efficacy. |
| ADME/Pharmacokinetics |
SU14813 is an orally bioavailable multi-targeted TKI. The compound is typically stored under appropriate conditions to maintain stability. Its physicochemical properties support its use in both in vitro and in vivo studies. SU14813's solubility and formulation for administration should be optimized based on specific experimental requirements. The compound is a next-generation TKI developed following sunitinib.
|
| Toxicity/Toxicokinetics |
SU14813 is a multi-targeted TKI with a well-characterized mechanism of action. As with any kinase inhibitor, potential toxicity may include off-target effects on other kinases and disruption of normal cellular signaling. The compound's safety profile should be evaluated in preclinical toxicology studies. SU14813 is for research use only and is not approved for human therapeutic use. It represents a valuable tool for studying multi-targeted kinase inhibition and angiogenesis.
|
| References | |
| Additional Infomation |
SU014813, a VEGFR2/PDGFR/c-Kit/Flt-3 inhibitor, is an orally potent tyrosine kinase receptor inhibitor with potential antitumor activity. SU014813 binds to and inhibits the phosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR) α and β, c-Kit, and Fms-associated tyrosine kinase 3 (Flt-3). This leads to inhibition of cell proliferation and angiogenesis, and induces apoptosis.
SU14813 (CAS# 627908-92-3) is a novel, orally bioavailable, multi-targeted tyrosine kinase inhibitor (TKI) with IC50s of 50 nM for VEGFR2, 2 nM for VEGFR1, 4 nM for PDGFRβ, and 15 nM for KIT. It is a next-generation TKI developed following sunitinib (SU11248), designed to exhibit optimized pharmacokinetic (PK) and tolerability profiles. SU14813 demonstrates broad and potent antitumor activity equivalent to that of sunitinib. The compound is for research use only and is not approved for human therapeutic use. |
| Molecular Formula |
C23H27FN4O4
|
|---|---|
| Molecular Weight |
442.48
|
| Exact Mass |
442.202
|
| Elemental Analysis |
C, 62.43; H, 6.15; F, 4.29; N, 12.66; O, 14.46
|
| CAS # |
627908-92-3
|
| Related CAS # |
SU14813 maleate;849643-15-8
|
| PubChem CID |
10138259
|
| Appearance |
white solid powder
|
| LogP |
2.284
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
32
|
| Complexity |
729
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
FC1C([H])=C([H])C2=C(C=1[H])/C(/C(N2[H])=O)=C(/[H])\C1=C(C([H])([H])[H])C(C(N([H])C([H])([H])[C@@]([H])(C([H])([H])N2C([H])([H])C([H])([H])OC([H])([H])C2([H])[H])O[H])=O)=C(C([H])([H])[H])N1[H]
|
| InChi Key |
CTNPALGJUAXMMC-ZDLGFXPLSA-N
|
| InChi Code |
InChI=1S/C23H27FN4O4/c1-13-20(10-18-17-9-15(24)3-4-19(17)27-22(18)30)26-14(2)21(13)23(31)25-11-16(29)12-28-5-7-32-8-6-28/h3-4,9-10,16,26,29H,5-8,11-12H2,1-2H3,(H,25,31)(H,27,30)/b18-10-
|
| Chemical Name |
5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-N-(2-hydroxy-3-morpholin-4-ylpropyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide
|
| Synonyms |
SU14813; SU 14813; SU-014813; SU 014813; SU-14813; SU014813
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 44~88 mg/mL (99.4~198.9 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.65 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.65 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2600 mL | 11.2999 mL | 22.5999 mL | |
| 5 mM | 0.4520 mL | 2.2600 mL | 4.5200 mL | |
| 10 mM | 0.2260 mL | 1.1300 mL | 2.2600 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT00982267
Conditions:Neoplasms|Solid TumorsLink: https://clinicaltrials.gov/ct2/show/NCT00322517
Conditions:Breast NeoplasmsProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA